Profile data is unavailable for this security.
About the company
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.
- Revenue in USD (TTM)16.15m
- Net income in USD-57.80m
- Incorporated2018
- Employees51.00
- LocationPyxis Oncology Inc321 Harrison Avenue, 11th Floor, Suite 1BOSTON 02118United StatesUSA
- Phone+1 (617) 453-3596
- Fax+1 (302) 655-5049
- Websitehttps://pyxisoncology.com/
More ▼
Mergers & acquisitions
| Acquired company | PYXS:NSQ since announced | Transaction value |
|---|---|---|
| Apexigen Inc | 13.00% | 15.88m |
Data delayed at least 15 minutes, as of May 17 2024 17:47 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ovid Therapeutics Inc | 473.53k | -50.68m | 231.90m | 40.00 | -- | 2.96 | -- | 489.74 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Prelude Therapeutics Inc | 0.00 | -125.55m | 235.10m | 128.00 | -- | 1.12 | -- | -- | -1.88 | -1.88 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 238.94m | 167.00 | -- | -- | -- | 1.28 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.40 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 82.75 | 69.13 | -22.98 | -82.25 | 1.31 | -5.00 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 243.01m | 10.00 | -- | 2.14 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 244.68m | 100.00 | -- | 8.81 | -- | 2.91 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Pyxis Oncology Inc | 16.15m | -57.80m | 245.51m | 51.00 | -- | 1.33 | -- | 15.21 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 33.90m | -92.95m | 247.42m | 116.00 | -- | -- | -- | 7.30 | -2.21 | -2.21 | 0.8046 | -2.29 | 0.108 | -- | -- | 292,206.90 | -29.61 | -31.35 | -35.75 | -35.69 | -- | -- | -274.23 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 248.95m | 249.00 | -- | -- | -- | 0.8247 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Generation Bio Co | 9.96m | -169.06m | 250.81m | 174.00 | -- | 1.90 | -- | 25.17 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Design Therapeutics Inc | 0.00 | -58.67m | 254.23m | 57.00 | -- | 0.9431 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 257.03m | 274.00 | -- | 1.24 | -- | 3.61 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Century Therapeutics Inc | 1.37m | -133.47m | 259.31m | 152.00 | -- | 1.14 | -- | 189.28 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| TriSalus Life Sciences Inc | 18.51m | -63.28m | 259.56m | 112.00 | -- | -- | -- | 14.02 | -1.84 | -1.84 | 0.5991 | -0.982 | 0.7758 | 1.30 | 7.24 | 165,267.90 | -247.43 | -- | -17,440.77 | -- | 85.93 | -- | -318.95 | -- | 1.25 | -13.69 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| XBiotech Inc | 0.00 | -30.74m | 261.30m | 92.00 | -- | 1.25 | -- | -- | -1.01 | -1.01 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -13.08 | 31.88 | -13.68 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0456 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Zura Bio Ltd | 0.00 | -60.18m | 261.56m | 14.00 | -- | 4.29 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Pyxis Oncology Inc's reporting currency: US Dollar USD
26.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ridgeback Capital Management LLCas of 26 Jan 2024 | 4.35m | 7.48% |
| Deep Track Capital LPas of 08 Mar 2024 | 4.18m | 7.20% |
| Laurion Capital Management LPas of 31 Dec 2023 | 3.17m | 5.45% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.39m | 2.39% |
| abrdn, Inc.as of 31 Mar 2024 | 708.30k | 1.22% |
| Vestal Point Capital LPas of 31 Dec 2023 | 440.00k | 0.76% |
| HHLR Advisors Ltd.as of 31 Dec 2023 | 382.61k | 0.66% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 364.15k | 0.63% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 309.51k | 0.53% |
| Geode Capital Management LLCas of 31 Dec 2023 | 308.24k | 0.53% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
